Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from The United Laboratories International Holdings ( (HK:3933) ).
The United Laboratories International Holdings announced that its wholly owned subsidiary, Zhuhai United Laboratories Zhongshan Branch, has obtained China’s quality and efficacy consistency evaluation approval for its 150mg Roxithromycin Capsules. The product, a second-generation macrolide antibiotic indicated for various infections and already listed as a Category B drug in the 2025 National Medical Insurance Drug List, is the first Roxithromycin capsule dosage form in China to pass this evaluation.
The company stated that this milestone will further strengthen its leading position in the anti-infective drug segment and support its competitive edge in the Chinese pharmaceutical market. Management added that it plans to continue investing in research and development of new products, aiming to enhance long-term value creation for the company and its shareholders.
The most recent analyst rating on (HK:3933) stock is a Hold with a HK$13.00 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
More about The United Laboratories International Holdings
The United Laboratories International Holdings Limited is a pharmaceutical company incorporated in the Cayman Islands and listed in Hong Kong. Through subsidiaries such as Zhuhai United Laboratories, it focuses on research, development and production of generic drugs, with a notable presence in anti-infective therapies in the Chinese healthcare market.
YTD Price Performance: 12.86%
Average Trading Volume: 9,857,843
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$25.81B
Learn more about 3933 stock on TipRanks’ Stock Analysis page.